Results 11 to 20 of about 6,140 (153)

Development and clinical application of a stability-indicating chromatography technique for the quantification of diazoxide

Heliyon, 2023
Diazoxide is a potential candidate for the treatment of transitional hypoglycaemia in infants. A clinical trial is currently underway to investigate whether low-dose oral diazoxide is beneficial for severe or recurrent transitional neonatal hypoglycaemia
Trusha J. Purohit, Don Laing, Christopher JD. McKinlay, Jane M. Alsweiler, Sara M. Hanning   +4 more
doaj   +1 more source

Diazoxide is a powerful cardioprotectant but is not feasible in a realistic infarct scenario

Frontiers in Cardiovascular Medicine, 2023
IntroductionDiazoxide is a powerful cardioprotective agent that activates mitochondrial ATP-dependent K-channels and stimulates mitochondrial respiration.
Petra Kleinbongard, Helmut Lieder, Andreas Skyschally, Gerd Heusch   +3 more
doaj   +1 more source

Diazoxide-Induced Hypertrichosis in a Neonate With Transient Hyperinsulinism

Clinical Medicine Insights: Case Reports, 2023
Diazoxide is one of the FDA-approved pharmacologic treatments for hyperinsulinemic hypoglycemia, however, its adverse effects in infants are not well described. We reported a 37-week-old boy with the diagnosis of hypoglycemia.
Seyyed Javad Boskabadi, Sima Ramezaninejad, Masoumeh Sohrab, Roya Farhadi   +3 more
doaj   +1 more source

Diazoxide Post-conditioning Activates the HIF-1/HRE Pathway to Induce Myocardial Protection in Hypoxic/Reoxygenated Cardiomyocytes

Frontiers in Cardiovascular Medicine, 2021
Background: Previous studies have shown that diazoxide can protect against myocardial ischemia-reperfusion injury (MIRI). The intranuclear hypoxia-inducible factor-1 (HIF-1)/hypoxia-response element (HRE) pathway has been shown to withstand cellular ...
Xi-Yuan Chen, Xi-Yuan Chen, Jia-Qi Wang, Si-Jing Cheng, Yan Wang, Meng-Yuan Deng, Tian Yu, Hai-Ying Wang, Wen-Jing Zhou, Wen-Jing Zhou   +9 more
doaj   +1 more source

Kir1.1 and SUR1 are not implicated as subunits of an adenosine triphosphate-sensitive potassium channel involved in diazoxide cardioprotectionCentral MessagePerspective

JTCVS Open, 2023
Objective: The adenosine triphosphate-sensitive potassium channel opener diazoxide mimics ischemic preconditioning and is cardioprotective. Clarification of diazoxide's site and mechanism of action could lead to targeted pharmacologic therapies for ...
Jie Wang, MD, Kyriakos Papanicolaou, PhD, Robert Tryon, PhD, Janelle Sangalang, BA, Ben Salazar, BS, Alejandro Suarez-Pierre, MD, Jie Dong, MD, Anson Lee, BS, BA, Emily Larson, BS, Sari Holmes, PhD, Brian O’Rourke, PhD, Colin Nichols, PhD, Jennifer Lawton, MD   +12 more
doaj   +1 more source

Evaluation of spasmolytic effects of naringenin on ileum contraction and intestinal charcoal meal transit: Involvement of ATP-sensitive K+ channels [PDF]

Journal of HerbMed Pharmacology, 2022
Introduction: Naringenin is a flavonoid constituent of many herbal plants, including citreous fruits. Biological studies have suggested various therapeutic effects for naringenin, including protective effects on gastrointestinal (GI) motility.
Hassan Sadraei, Maedeh Ghasemi, Salman Saranji   +2 more
doaj   +1 more source

ATP—Sensitive Potassium Channel Opener Diazoxide Reduces Myocardial Stunning in a Porcine Regional With Subsequent Global Ischemia Model

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background ATP‐sensitive potassium channels are inhibited by ATP and open during metabolic stress, providing endogenous myocardial protection. Pharmacologic opening of ATP potassium channels with diazoxide preserves myocardial function following ...
Ana K. Velez, Eric Etchill, Katherine Giuliano, Sean Kearney, Melissa Jones, Jie Wang, Brian Cho, Mary Beth Brady, Jeffrey Dodd‐o, Joseph M. Meyer, Jennifer S. Lawton   +10 more
doaj   +1 more source

Ubiquinol-cytochrome c reductase core protein 1 may be involved in delayed cardioprotection from preconditioning induced by diazoxide. [PDF]

PLoS ONE, 2017
This study aimed to use long-term diazoxide treatment to establish a loss-of-cardioprotection model and then perform proteomics analysis to explore which proteins of mitochondrial inner membrane (MIM) are potentially involved in delayed cardioprotection.
Zonghong Long, Guangyou Duan, Hong Li, Tingting Yi, Xiaoxiao Wu, Feng Chen, Zhuoxi Wu, Yuqi Gao   +7 more
doaj   +1 more source

Pulmonary hypertension associated with diazoxide: the SUR1 paradox

ERJ Open Research, 2023
The ATP-sensitive potassium channels and their regulatory subunits, sulfonylurea receptor 1 (SUR1/Kir6.2) and SUR2/Kir6.1, contribute to the pathophysiology of pulmonary hypertension (PH).
David Montani, Fabrice Antigny, Etienne-Marie Jutant, Marie-Camille Chaumais, Hélène Le Ribeuz, Julien Grynblat, Charles Khouri, Marc Humbert   +7 more
doaj   +1 more source

A Rare Side Effect of Diazoxide Therapy: Pulmonary Hipertension

Journal of Behçet Uz Children's Hospital, 2020
We present a newborn diagnosed with Beckwith-Wiedemann syndrome and hypoglycemia, and developed pulmonary hypertension due to initiated diazoxide treatment because of these indications.
Alper Hazım Gürsu, Emine Azak, Eda Mengen, Sevim Ünal, Ibrahim Ilker Cetin   +4 more
doaj   +1 more source